A functional epidermal growth factor (EGF) polymorphism, EGF serum levels, and esophageal adenocarcinoma risk and outcome

Clinical Cancer Research

Volumn 14, Issue 10, 2008, Pages 3216-3222

  Lanuti, Michael ^a,b   Liu, Geoffrey ^b,f,g   Goodwin, Jonathan M ^a   Zhai, Rihong ^f   Fuchs, Bryan C ^c   Asomaning, Kofi ^f   Su, Li ^f   Nishioka, Norman S ^e   K tanabe, Kenneth ^b,c   Christiani, David C ^d,f  

^a Division of Thoracic Surgery   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c Division of Surgical Oncology   (United States)

^d Pulmonary and Critical Care Division   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; FEMALE; GENETIC RISK; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; RISK ASSESSMENT; RISK FACTOR; ADENOCARCINOMA; BLOOD; CASE CONTROL STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS TUMOR; GASTROESOPHAGEAL REFLUX; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; PRECANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BARRETT ESOPHAGUS; CASE-CONTROL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL GROWTH FACTOR; ESOPHAGEAL NEOPLASMS; FEMALE; GASTROESOPHAGEAL REFLUX; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECANCEROUS CONDITIONS; RISK FACTORS; TREATMENT OUTCOME;

EID: 49649095642     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4932     Document Type: Article

References (31)

1. Aklilu M, lison DH. Targeted agents and esophageal cancer-the next step? Semin Radiat Oncol 2006;17: 62-9.
2. Holmes RS, Vaughan TL. Epidemiology and pathogenesis of esophageal cancer. Semin Radiat Oncol 2006;17:2-9.
3. de Jonge P, Steyerberg EW, Kuipers EJ, et al. Risk factors for the development of esophageal adenocarcinoma in BE. Am J Gastroenterol 2006;101: 1421 -9.
4. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241 -52.
5. Fitzgerald, RC. Molecular basis of Barrett's oesophagus and oesophageal adenocarcinoma. Gut 2006;55: 1810-8.
6. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: scientific review. JAMA 2002;287:1972-81.
7. Lagarde SM, ten Kate FJW, Richel DJ. Offerhaus GJA, van Lanschot JJB. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction. Ann Surg Oncol 2007;14: 977-91.
8. Lu SH, Hsieh LL, Luo FC. Weinstein IB. Amplification of the EGF receptor and c-myc genes in human esophageal cancer. Int J Cancer1988;42:502-5.
9. Hollstein MC, Smits AM, Galiana C, et al. Amplification of epidermal growth gene but no evidence for ras mutations in primary human esophageal cancers. Cancer Res 1988;48:5119-23.
10. Stoscheck CM, King LE. Role of epidermal growth factor in carcinogenesis. Cancer Res1986;46:1030-7.
11. Costa BM, Ferreira P, Costa S, et al. Association between functional EGF +61 polymorphism and glioma risk. Clin Cancer Res 2007;13:2621 -6.
12. Bhowmick DA, Zhuang Z, Wait SD,Weil RJ. A functional polymorphism in the EGF gene is found with increased frequency in glioblastoma multiforme patients and is associated with more aggressive disease. Cancer Res 2004;64:1220-3.
13. Shahbazi M, Pravica V, Nasreen N, et al. Association between functional polymorphism in EGF gene and malignant melanoma. Lancet 2002;359:397-401.
14. Okamoto I, Roka F, Krogler J. et al. The EGF A61G polymorphism is associated with disease free period and survival in malignant melanoma. J Invest Dermatol 2007;127:969-70.
15. Hamai Y, Matsumura S, Matsusaki K, et al. A single nucleotide polymorphism in the 5' untranslated region of the EGF gene is associated with occurrence and malignant progression of gastric cancer. Pathobiology 2005;72:133-8.
16. Lim YJ, Kim JW. Song JY et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett 2005;374:157-60.
17. 17.Tanabe KK, Lemoine A, Finkelstein DM, et al. A functional polymorphism in the EGF gene increases the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008;299:53-60.
18. Oka Y, Orth DN. Human plasma epidermal growth factor/β-urogastrone is associated with blood platelets. J Clin Invest 1983;72:249-59.
19. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, NCI US and Canada. J Natl Cancer Inst 2000;92:205-16.
20. Li Y, Wo JM, Ray MB, et al. Cyclooxygenase 2 and epithelial growth factor up-regulation during progression of BE to adenocarcinoma. World J. Gastroenterol 2006;12:928-34.
21. Niklinski J, Niklinska W, Chyczewski L, Becker HD, Pluygers E. Molecular genetic abnormalities in pre malignant lung lesions: biological and clinical implications. Eur J Cancer Prev 2001;10:213-26.
22. Shibata T, Hanada S. Kokubu A. et al. Gene expression profiling of epidermal growth factor receptor KRAS pathway activation in lung adenocarcinoma Cancer Sci 2007;98:985-91
23. Liu G, Zhou W.Yeap BY, et al XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk Carcinogenesis 2007;28:1254-8
24. Amend KL, Elder JT. Tomsho LP, et al. EGF gene polymorphism and the risk of incident primary melanoma. Cancer Res 2004;64:2668-72
25. McCarron SL, Bateman AC, Theaker JM, Howell WM. EGF +61 gene polymorphism and susceptibility to and prognostic markers in cutaneous malignant melanoma Int J Cancer 2003;107:673 - 5
26. Goto Y, Ando T, Goto H, Hamajima N No association between EGF gene polymorphism and gastric cancer. Cancer Epidemiol Biomarkers Prev 2005;11 2454-6.
27. Vauleon E, Auger N, Benouaich-Amiel A, et al. The 61A/G EGF polymorphism is functional but is neither a prognostic marker nor a risk factor for glioblastoma Cancer Genet Cytogenet 2007;1.33 - 7.
28. Kang S, Kim JW, Park NH, et al. Epidermal growth factor 61 A/G polymorphism and uterine cervical cancer. Int J Gynecol Cancer 2007;17:492 6
29. Casson AG, Tammemagi M, Eskandarian S. Redston M, McLaughling J, Ozcelik H. p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival Mol Pathol 1998. 51:71 -9.
30. Casson AG, Zheng Z, Evans SC, et al. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma. Cancer 2005:104:730- 9.
31. Izzo JG.Wu TT, Wu X, et al. Cyclin D1 Guanine/adenine 870 polymorphism with altered protein expression is associated with genomic instability and aggressive clinical biology of esophageal adenocarcinoma. J Clin Onc 2007;25:698- 706